JP6090867B2 - ウコン油及びビサボレンセスキテルペノイドの抗痙攣活性 - Google Patents
ウコン油及びビサボレンセスキテルペノイドの抗痙攣活性 Download PDFInfo
- Publication number
- JP6090867B2 JP6090867B2 JP2014517788A JP2014517788A JP6090867B2 JP 6090867 B2 JP6090867 B2 JP 6090867B2 JP 2014517788 A JP2014517788 A JP 2014517788A JP 2014517788 A JP2014517788 A JP 2014517788A JP 6090867 B2 JP6090867 B2 JP 6090867B2
- Authority
- JP
- Japan
- Prior art keywords
- turmerone
- ptz
- turmeric
- seizures
- zebrafish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000010681 turmeric oil Substances 0.000 title claims description 63
- 239000001961 anticonvulsive agent Substances 0.000 title description 73
- 230000001773 anti-convulsant effect Effects 0.000 title description 53
- 230000000694 effects Effects 0.000 title description 50
- 229960003965 antiepileptics Drugs 0.000 title description 46
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 65
- NAAJVHHFAXWBOK-ZDUSSCGKSA-N (+)-(S)-ar-turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CC=C(C)C=C1 NAAJVHHFAXWBOK-ZDUSSCGKSA-N 0.000 claims description 51
- XOCANRBEOZQNAQ-KGLIPLIRSA-N ar-turmerone Natural products C[C@H](CC(=O)C=C(C)C)[C@@H]1CC=C(C)C=C1 XOCANRBEOZQNAQ-KGLIPLIRSA-N 0.000 claims description 51
- 244000163122 Curcuma domestica Species 0.000 claims description 49
- 235000003373 curcuma longa Nutrition 0.000 claims description 32
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 30
- 206010015037 epilepsy Diseases 0.000 claims description 30
- 235000013976 turmeric Nutrition 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 17
- 235000014375 Curcuma Nutrition 0.000 claims description 16
- XBGUIVFBMBVUEG-UHFFFAOYSA-N 1-methyl-4-(1,5-dimethyl-4-hexenylidene)-1-cyclohexene Chemical compound CC(C)=CCCC(C)=C1CCC(C)=CC1 XBGUIVFBMBVUEG-UHFFFAOYSA-N 0.000 claims description 11
- YHBUQBJHSRGZNF-HNNXBMFYSA-N alpha-bisabolene Natural products CC(C)=CCC=C(C)[C@@H]1CCC(C)=CC1 YHBUQBJHSRGZNF-HNNXBMFYSA-N 0.000 claims description 11
- 229930003493 bisabolene Natural products 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000407170 Curcuma Species 0.000 claims 1
- 230000002082 anti-convulsion Effects 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 description 89
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 71
- 229960005152 pentetrazol Drugs 0.000 description 68
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 49
- 241000252212 Danio rerio Species 0.000 description 48
- JIJQKFPGBBEJNF-UHFFFAOYSA-N curlone Chemical compound CC(C)=CC(=O)CC(C)C1CCC(=C)C=C1 JIJQKFPGBBEJNF-UHFFFAOYSA-N 0.000 description 30
- OJEFBZMKKJTKKK-UHFFFAOYSA-N cis-alpha-Atlanton Natural products CC(C)=CC(=O)C=C(C)C1CCC(C)=CC1 OJEFBZMKKJTKKK-UHFFFAOYSA-N 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- 235000012754 curcumin Nutrition 0.000 description 24
- 229940109262 curcumin Drugs 0.000 description 24
- 239000004148 curcumin Substances 0.000 description 24
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 229940125681 anticonvulsant agent Drugs 0.000 description 18
- XOCANRBEOZQNAQ-UHFFFAOYSA-N α-turmerone Chemical compound CC(C)=CC(=O)CC(C)C1CC=C(C)C=C1 XOCANRBEOZQNAQ-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000006399 behavior Effects 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 15
- 230000033001 locomotion Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 11
- 229960003529 diazepam Drugs 0.000 description 11
- 208000015114 central nervous system disease Diseases 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000000366 juvenile effect Effects 0.000 description 10
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- 208000015122 neurodegenerative disease Diseases 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 8
- 230000036461 convulsion Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 229960002036 phenytoin Drugs 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- 206010061334 Partial seizures Diseases 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 229940084026 sodium valproate Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 208000037158 Partial Epilepsies Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 201000007186 focal epilepsy Diseases 0.000 description 6
- 210000003194 forelimb Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 231100000161 signs of toxicity Toxicity 0.000 description 6
- 230000001256 tonic effect Effects 0.000 description 6
- 208000020925 Bipolar disease Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 208000037012 Psychomotor seizures Diseases 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010009346 Clonus Diseases 0.000 description 4
- 229930153442 Curcuminoid Natural products 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000002566 clonic effect Effects 0.000 description 4
- 239000003179 convulsant agent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000004720 fertilization Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100033639 Acetylcholinesterase Human genes 0.000 description 3
- 108010022752 Acetylcholinesterase Proteins 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- 206010053398 Clonic convulsion Diseases 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- HJTVQHVGMGKONQ-LUZURFALSA-N demethoxycurcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 230000004973 motor coordination Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000011808 rodent model Methods 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 238000001256 steam distillation Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000012762 unpaired Student’s t-test Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283070 Equus zebra Species 0.000 description 2
- 206010016173 Fall Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- -1 Small molecule compounds Chemical class 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 208000028329 epileptic seizure Diseases 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 2
- 238000009160 phytotherapy Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010008359 protein kinase C lambda Proteins 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940109566 valproic acid 300 mg Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- DAKZWTGWTHYJBT-FCXRPNKRSA-N (1e,6e)-1-[4-hydroxy-3-(methoxymethoxy)phenyl]-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione Chemical compound C1=C(O)C(OCOC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 DAKZWTGWTHYJBT-FCXRPNKRSA-N 0.000 description 1
- ICDNYWJQGWNLFP-VXGBXAGGSA-N (2S)-2-[(R)-(2-chlorophenyl)-hydroxymethyl]-3-methoxy-2H-furan-5-one Chemical compound COC1=CC(=O)O[C@H]1[C@H](O)C1=CC=CC=C1Cl ICDNYWJQGWNLFP-VXGBXAGGSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 208000037823 Cerebral ischemia/reperfusion injury Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 244000164418 Curcuma xanthorrhiza Species 0.000 description 1
- 235000003393 Curcuma xanthorrhiza Nutrition 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241001397484 Heracleum crenatifolium Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000032014 Java citronella Species 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000989313 Peltophorum dasyrhachis Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GQRYDKSIXWXTSH-NXZHAISVSA-N [4-[(1e,6e)-7-(4-acetyloxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenyl] acetate Chemical compound C1=C(OC(C)=O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(OC(C)=O)=CC=2)=C1 GQRYDKSIXWXTSH-NXZHAISVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- 150000002553 bisabolene derivatives Chemical class 0.000 description 1
- NRBFEAZFHRHFFQ-ZFWWWQNUSA-N bisacumol Natural products CC(C)=C[C@H](O)C[C@H](C)C1=CC=C(C)C=C1 NRBFEAZFHRHFFQ-ZFWWWQNUSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 235000021532 culinary herbs Nutrition 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000028326 generalized seizure Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 229950009284 losigamone Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000002436 one-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000024188 startle response Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1111319.8A GB201111319D0 (en) | 2011-07-04 | 2011-07-04 | Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa |
| GB1111319.8 | 2011-07-04 | ||
| PCT/EP2012/063027 WO2013004740A1 (en) | 2011-07-04 | 2012-07-04 | Anticonvulsant activity of turmeric oil and bisabolene sesquiterpenoids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518241A JP2014518241A (ja) | 2014-07-28 |
| JP2014518241A5 JP2014518241A5 (enExample) | 2015-08-20 |
| JP6090867B2 true JP6090867B2 (ja) | 2017-03-08 |
Family
ID=44512006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517788A Active JP6090867B2 (ja) | 2011-07-04 | 2012-07-04 | ウコン油及びビサボレンセスキテルペノイドの抗痙攣活性 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9782361B2 (enExample) |
| EP (1) | EP2729138B8 (enExample) |
| JP (1) | JP6090867B2 (enExample) |
| ES (1) | ES2661844T3 (enExample) |
| GB (1) | GB201111319D0 (enExample) |
| IN (1) | IN2013DN11328A (enExample) |
| WO (1) | WO2013004740A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101517843B1 (ko) | 2013-09-30 | 2015-05-08 | 한국인스팜(주) | 울금 비극성용매 가용 추출물 또는 이로부터 분리된 아로매틱-튜메론을 유효성분으로 함유하는 스트레스관련 질환의 치료 및 예방을 위한 조성물 |
| JP6773361B2 (ja) * | 2015-04-09 | 2020-10-21 | ハウスウェルネスフーズ株式会社 | 気分状態改善剤 |
| JP6883845B2 (ja) * | 2017-03-17 | 2021-06-09 | 学校法人早稲田大学 | アストロサイト分化促進用組成物 |
| US12295920B2 (en) | 2018-06-29 | 2025-05-13 | House Wellness Foods Corporation | Composition for treatment, prevention, or amelioration of Alzheimer's disease, a composition for suppression of brain nerve cell death, a composition for suppression of microglia activation induced by amyloid β peptide, and a composition for suppression of PGE2, TNF-α, or IL-1β production induced by amyloid βpeptide |
| CN110721175A (zh) * | 2018-07-17 | 2020-01-24 | 文小燕 | 姜黄提取物在制备治疗癫痫的药物中的用途 |
| FR3098396B1 (fr) * | 2019-07-10 | 2022-07-29 | Indigo Therapeutics | Composition pour le traitement des troubles des émotions |
| CN113759007B (zh) * | 2020-08-25 | 2023-03-21 | 北京康仁堂药业有限公司 | 一种广西莪术的质量控制方法 |
| US20250195601A1 (en) * | 2023-12-18 | 2025-06-19 | Universidad De Cuenca | Turmeric oil essential-oil bisabolene sesquiterpenoids in the treatment of non-neurodegenerative diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051380A2 (en) | 2001-12-14 | 2003-06-26 | Council Of Scientific And Industrial Research | Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| JP2004331539A (ja) * | 2003-05-06 | 2004-11-25 | Maruzen Pharmaceut Co Ltd | 肝臓疾患予防治療剤及び肝臓疾患予防治療用飲食物 |
| US20080193573A1 (en) * | 2006-03-17 | 2008-08-14 | Gow Robert T | Extracts and methods comprising curcuma species |
| CN101199833B (zh) * | 2007-12-21 | 2011-03-16 | 北京中科雍和医药技术有限公司 | 一种缓解关节炎疼痛的复方精油 |
| TW201019949A (en) | 2008-10-16 | 2010-06-01 | Herbalscience Group Llc | Extracts of curcuma and methods of use thereof |
| EP2458983B1 (en) * | 2009-07-31 | 2015-07-08 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| WO2011080090A1 (en) | 2009-12-31 | 2011-07-07 | Arcelik Anonim Sirketi | A dishwasher comprising a microfilter |
| AU2011228689A1 (en) * | 2010-03-15 | 2012-09-27 | Laila Nutraceuticals | Boswellia oil, its fractions and compositions for enhancing brain function |
| EP2555787B1 (en) * | 2010-04-05 | 2017-11-08 | Benny Antony | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
-
2011
- 2011-07-04 GB GBGB1111319.8A patent/GB201111319D0/en not_active Ceased
-
2012
- 2012-07-04 WO PCT/EP2012/063027 patent/WO2013004740A1/en not_active Ceased
- 2012-07-04 EP EP12735494.2A patent/EP2729138B8/en active Active
- 2012-07-04 IN IN11328DEN2013 patent/IN2013DN11328A/en unknown
- 2012-07-04 ES ES12735494.2T patent/ES2661844T3/es active Active
- 2012-07-04 JP JP2014517788A patent/JP6090867B2/ja active Active
- 2012-07-04 US US14/130,702 patent/US9782361B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013004740A1 (en) | 2013-01-10 |
| US20140243420A1 (en) | 2014-08-28 |
| EP2729138B8 (en) | 2018-02-28 |
| JP2014518241A (ja) | 2014-07-28 |
| IN2013DN11328A (enExample) | 2015-05-15 |
| EP2729138A1 (en) | 2014-05-14 |
| GB201111319D0 (en) | 2011-08-17 |
| US9782361B2 (en) | 2017-10-10 |
| EP2729138B1 (en) | 2017-12-13 |
| ES2661844T3 (es) | 2018-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6090867B2 (ja) | ウコン油及びビサボレンセスキテルペノイドの抗痙攣活性 | |
| Orellana-Paucar et al. | Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models | |
| Heo et al. | Effect of antioxidant flavanone, naringenin, from Citrus junos on neuroprotection | |
| Fumia et al. | Role of nutraceuticals on neurodegenerative diseases: Neuroprotective and immunomodulant activity | |
| Bian et al. | Scutellarin protects against lipopolysaccharide-induced behavioral deficits by inhibiting neuroinflammation and microglia activation in rats | |
| Lee et al. | Synergistic effect of natural compounds on the fatty acid-induced autophagy of activated hepatic stellate cells | |
| Durg et al. | Antipsychotic activity of embelin isolated from Embelia ribes: A preliminary study | |
| Taiwe et al. | Anticonvulsant activity of an active fraction extracted from Crinum jagus L.(Amaryllidaceae), and its possible effects on fully kindled seizures, depression-like behaviour and oxidative stress in experimental rodent models | |
| Adzu et al. | Isolation and analgesic property of lupeol from Diospyros mespiliformis stem bark | |
| Li et al. | Antidepressant-like effect of macranthol isolated from Illicium dunnianum tutch in mice | |
| Chen et al. | Targeting the TLR4/NF-κB pathway in β-amyloid-stimulated microglial cells: A possible mechanism that oxysophoridine exerts anti-oxidative and anti-inflammatory effects in an in vitro model of Alzheimer’s disease | |
| Fongang et al. | Antinociceptive and anti-inflammatory effects of the methanolic stem bark extract of Antrocaryon klaineanum Pierre (Anacardiaceae) in mice and rat | |
| Knap et al. | Zebrafish as a robust preclinical platform for screening plant-derived drugs with anticonvulsant properties—a review | |
| Moradi Vastegani et al. | Anti-inflammatory, anti-apoptotic, and neuroprotective potentials of anethole in Parkinson’s disease-like motor and non-motor symptoms induced by rotenone in rats | |
| Sałaga et al. | Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice | |
| JP2017513807A (ja) | 丹参の抽出物及び化合物 | |
| Zhang et al. | Neuroprotective effects of bavachin against neuroinflammation and oxidative stress-induced neuronal damage via activation of Sirt1/Nrf2 pathway and inhibition of NF-κB pathway | |
| Bevilacqua et al. | Toxicity of apolar and polar Lantana camara L. crude extracts in mice | |
| Taïwe et al. | Neurotoxicity and neuroprotective effects of African medicinal plants | |
| KR101300798B1 (ko) | 곰취 추출물을 포함하는 뇌신경세포 보호용 조성물 | |
| Bhowmick et al. | Curcuma longa extract ameliorates motor and cognitive deficits of 6-hydroxydopamine-infused Parkinson’s disease model rats | |
| Ioniță et al. | 6-Hydroxy-l-nicotine effects on anxiety and depression in a rat model of chlorisondamine | |
| Gorain et al. | Mechanistic description of natural herbs in the treatment of dementia: a systematic review | |
| ES2909387T3 (es) | Extractos de plantas enriquecidos con derivados de ipolamiida como inmunosupresores para tratar trastornos inmunológicos | |
| Pandey | Therapeutic potential of Vachadi ghrita (a medicated ghee) on CNS and other ailments—a review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150703 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170202 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6090867 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |